ALK and non-small cell lung carcinoma: Furthermore, while AP26113 may show slight efficacy in overcoming ALK+ ALCL resistance acquired by this mutation (p = 0.0513), it is predicted to be ineffective in ALK+ NSCLC, with the opposite being true for AZD3463 with respect to each disease.